LOGIN  |  REGISTER
Cue Biopharma

Orthofix Medical to Participate in Upcoming Investor Conferences

November 12, 2024 | Last Trade: US$18.87 0.14 0.75

LEWISVILLE, Texas / Nov 12, 2024 / Business Wire / Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Massimo Calafiore, President and Chief Executive Officer, and Julie Andrews, Chief Financial Officer, will participate in the following investor conferences:

  • Stifel 2024 Healthcare Conference in New York, NY, November 18, 2024, fireside chat at 8:35 AM Eastern Time
  • Stifel MedTech Madness 2024 Annual West Coast Bus Tour in Laguna Beach, CA, December 9, 2024, fireside chat at 8:00 AM Pacific Time

Live webcasts and replays, when available, can be found under "Events & Presentations" in the Investors section of the Orthofix website at https://ir.orthofix.com/events-and-presentations/.

About Orthofix

Orthofix is a global medical technology company headquartered in Lewisville, Texas. By providing medical technologies that heal musculoskeletal pathologies, we deliver exceptional experiences and life-changing solutions to patients around the world. Orthofix offers a comprehensive portfolio of spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, including the 7D FLASH™ navigation system. To learn more, visit Orthofix.com and follow on LinkedIn.

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB